Sabra Health Care REITの空売り状況は、投資家がSabra Health Care REITの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Sabra Health Care REIT (NASDAQ:SBRA) 株価情報, 空売り情報

Sabra Health Care REIT

Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.

Sabra Health Care REIT, Inc. - Common Stock

Sabra Health Care REIT Inc

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/27/final-trades-amazon-sabra-health-care-and-the-ieo.html">Halftime Report Final Trades</a>,&#8221; Jenny Van Leeuwen Harrington of Gilman Hill Asset Management picked Sabra Health Care REIT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>).
On Dec. 5, Mizuho analyst Vikram Malhotra downgraded the rating for Sabra Health Care REIT from Outperform to Neutral and maintained the price target of $20.
On Oct. 31, Sabra Health Care REIT reported quarterly earnings of 35 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $178 million which beat the analyst consensus estimate of $172.34 million.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joshua Brown of Ritholtz Wealth Management said he <a href="https://www.benzinga.com/quote/IEO">remains long on</a> iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEO#NYSE">IEO</a>).
Kevin Simpson of Capital Wealth Planning named Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) as his final trade.
On Dec. 20, Tigress Financial analyst Ivan Feinseth maintained Amazon.com with a Buy rating and raised the price target from $245 to $290.
Amid peak holiday shopping, Amazon.com recently announced that its operations will remain unaffected despite a strike initiated by workers at seven<a href="https://www.benzinga.com/news/24/12/42577506/amazon-shares-rise-as-company-says-operations-remain-unaffected-despite-workers-at-seven-us-facilities-going-on-strike-amid-peak-holiday-shopping"> of its U.S. facilities</a>.
Price Action:
<ul>
<li>iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF rose 0.1% during Friday's session.</li>
<li>Amazon shares fell 1.4% to close at $223.79 during Friday's session.</li>
<li>Sabra Health Care REIT fell 0.5% to settle at $17.02 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>
Image: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

AMZN

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

SBRA

Sabra Health Care REIT, Amazon And More: CNBC's 'Final Trades'

CNBC Final Trades: iShares US Oil & Gas Exploration & Production ETF, Amazon, Sabra Health Care REIT

During the last three months, 4 analysts shared their evaluations of Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.5, a high estimate of $20.00, and a low estimate of $18.00. This current average reflects an increase of 11.43% from the previous average price target of $17.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733407225_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Sabra Health Care REIT among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sabra Health Care REIT. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Sabra Health Care REIT's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sabra Health Care REIT's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Breaking Down Sabra Health Care REIT's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sabra Health Care REIT's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Sabra Health Care REIT's net margin is impressive, surpassing industry averages. With a net margin of 16.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sabra Health Care REIT's ROA stands out, surpassing industry averages. With an impressive ROA of 0.56%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.91.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Sabra Health Care REIT's Future

Mizuho analyst Vikram Malhotra downgrades Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) from Outperform to Neutral and maintains the price target from $20 to $20.

Downgrades

Price Target

Mizuho Downgrades Sabra Health Care REIT to Neutral, Maintains Price Target to $20

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) raises FY2024 FFO guidance from $1.36-1.39 to $1.39-1.40 vs $1.38 analyst estimate..

Guidance

Sabra Health Care REIT Raises FY2024 FFO Guidance from $1.36-1.39 to $1.39-1.40 vs $1.38 Est

2024 GUIDANCE
Sabra is updating its 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):
Updated Guidance
<ul>
<li>Net Income: $0.48 - $0.49</li>
<li>FFO: $1.35 - $1.36</li>
<li>Normalized FFO: $1.39 - $1.40</li>
<li>AFFO: $1.41 - $1.42</li>
<li>Normalized AFFO: $1.43 - $1.44</li>
</ul>
Previous Guidance
<ul>
<li>Net Income: $0.48 - $0.51</li>
<li>FFO: $1.33 - $1.36</li>
<li>Normalized FFO: $1.36 - $1.39</li>
<li>AFFO: $1.39 - $1.42</li>
<li>Normalized AFFO: $1.41 - $1.44 Guidance ranges assume year-over-year same store Cash NOI growth in the mid-to-high teens for the managed senior housing portfolio. Guidance also incorporates all announced investment and disposition activity, as well as announced activity under the at-the-market equity offering program. Guidance does not assume additional investment, disposition or capital transactions beyond those already disclosed. The foregoing guidance ranges reflect management's view of current and future market conditions. There can be no assurance that the Company's actual results will not differ materially from the estimates set forth above. Except as otherwise required by law, the Company assumes no, and hereby disclaims any, obligation to update any of the foregoing guidance ranges as a result of new information or new or future developments.</li>
</ul>
Commenting on the third quarter's results, Rick Matros, CEO and Chair, said, "It feels good to be providing essentially the same update as the last several quarters. Skilled nursing and managed senior housing continue to see higher occupancy and margins. EBITDARM coverage for our skilled nursing portfolio has surpassed 2019 levels, while our triple net senior housing portfolio is approaching that milestone. Among our key triple-net relationships, the only tenant that saw a sequential coverage decline was Avamere, but that was specifically due to the percentage rent we have been collecting as performance improves. Avamere's coverage remains healthy, and the lease restructure has worked out exactly as anticipated.
Leverage continues to tick down. Investments for the quarter and subsequent to quarter end totaled roughly $100 million, including those previously announced. Our investment pipeline has seen increased activity, and we are currently reviewing more potential investments than we have seen all year.
Additionally, we have increased the midpoint of our guidance, which implies year-over-year earnings growth of more than 6% for the full year."

Sabra Health Care REIT Revises FY24 Normalized AFFO From $1.41-$1.44 To $1.43-$1.44; Normalized FFO From $1.36-$1.39 To $1.39-$1.40

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.35 per share which met the analyst consensus estimate. This is a 6.06 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $178.00 million which beat the analyst consensus estimate of $172.34 million by 3.28 percent. This is a 10.13 percent increase over sales of $161.63 million the same period last year.

Earnings

Earnings Beats

Sabra Health Care REIT Q3 FFO $0.35, Inline, Sales $178.00M Beat $172.34M Estimate

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is preparing to release its quarterly earnings on Thursday, 2024-10-31. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Sabra Health Care REIT to report an earnings per share (EPS) of $0.35.
The market awaits Sabra Health Care REIT's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 1.2% drop in the share price the following trading session.
Here's a look at Sabra Health Care REIT's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.35</td>
<td>0.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.35</td>
<td>0.35</td>
<td>0.32</td>
<td>0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<h3>Analyst Insights on Sabra Health Care REIT</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Sabra Health Care REIT.
Sabra Health Care REIT has received a total of 5 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $18.6, the consensus suggests a potential 3.48% downside.
<h3>Peer Ratings Overview</h3>
The below comparison of the analyst ratings and average 1-year price targets of CareTrust REIT, American Healthcares and National Health Investors, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for CareTrust REIT, with an average 1-year price target of $33.25, suggesting a potential 72.55% upside.</li>
<li>American Healthcares is maintaining an Buy status according to analysts, with an average 1-year price target of $25.1, indicating a potential 30.25% upside.</li>
<li>The consensus among analysts is an Neutral trajectory for National Health Investors, with an average 1-year price target of $85.33, indicating a potential 342.81% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for CareTrust REIT, American Healthcares and National Health Investors, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabra Health Care REIT</td>
<td>Buy</td>
<td>9.29%</td>
<td>$121.39M</td>
<td>0.87%</td>
</tr>
<tr>
<td>CareTrust REIT</td>
<td>Outperform</td>
<td>16.05%</td>
<td>$53.18M</td>
<td>0.59%</td>
</tr>
<tr>
<td>American Healthcares</td>
<td>Buy</td>
<td>9.41%</td>
<td>$102.02M</td>
<td>0.10%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>Neutral</td>
<td>9.11%</td>
<td>$82.17M</td>
<td>2.83%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sabra Health Care REIT ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating and at the bottom for Return on Equity.
<h3>Discovering Sabra Health Care REIT: A Closer Look</h3>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>A Deep Dive into Sabra Health Care REIT's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Sabra Health Care REIT displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.29%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Sabra Health Care REIT's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sabra Health Care REIT's ROE excels beyond industry benchmarks, reaching 0.87%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sabra Health Care REIT's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.45% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average at 0.9, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SBRA/earnings">To track all earnings releases for Sabra Health Care REIT visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Sabra Health Care REIT's Earnings Preview

Scotiabank analyst Nicholas Yulico maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Sector Perform and raises the price target from $17 to $18.

Scotiabank Maintains Sector Perform on Sabra Health Care REIT, Raises Price Target to $18

Analysts' ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sabra Health Care REIT and provided 12-month price targets. The average target is $18.75, accompanied by a high estimate of $20.00 and a low estimate of $17.00. Marking an increase of 17.19%, the current average surpasses the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1727805692_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Sabra Health Care REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sabra Health Care REIT. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sabra Health Care REIT's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sabra Health Care REIT's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>All You Need to Know About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Unraveling the Financial Story of Sabra Health Care REIT</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Sabra Health Care REIT's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.29%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sabra Health Care REIT's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sabra Health Care REIT's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.87% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Sabra Health Care REIT's ROA stands out, surpassing industry averages. With an impressive ROA of 0.45%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average at 0.9, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Sabra Health Care REIT

Wells Fargo analyst John Kilichowski assumes Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Overweight rating and raises Price Target to $20.

Initiation

Wells Fargo Assumes Sabra Health Care REIT at Overweight, Raises Price Target to $20

Ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $17.75, with a high estimate of $20.00 and a low estimate of $16.00. This upward trend is evident, with the current average reflecting a 12.7% increase from the previous average price target of $15.75.
<img src="https://www.benzinga.com/files/images/story/2024/1726236032_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Sabra Health Care REIT among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sabra Health Care REIT. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sabra Health Care REIT's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sabra Health Care REIT's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Financial Insights: Sabra Health Care REIT</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Sabra Health Care REIT's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.29% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sabra Health Care REIT's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.87%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sabra Health Care REIT's ROA stands out, surpassing industry averages. With an impressive ROA of 0.45%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sabra Health Care REIT Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Citigroup analyst Nicholas Joseph upgrades Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) from Neutral to Buy and raises the price target from $17 to $20.

Upgrades

Citigroup Upgrades Sabra Health Care REIT to Buy, Raises Price Target to $20

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Buy and raises the price target from $16 to $18.

Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $18

Editor's Note: This article has been updated to reflect that the data was released on Wednesday.
Positive news has emerged for U.S. homebuyers navigating the housing market, as the average interest rate on 30-year fixed-rate mortgages with conforming loan balances (up to $766,550) declined to 6.50% in the week ending Aug. 16, according to data released Wednesday by <a href="https://www.benzinga.com/topic/mortgages">the Mortgage Bankers Association. </a>
This represents the lowest level since early May 2023. The decrease in mortgage rates aligns with a dip in long-term Treasury yields, influenced by market expectations of multiple rate cuts from the Federal Reserve this year.
Last week, the 30-year Treasury yield dropped by 7 basis points, currently on track for a fourth straight month of declines. Month-to-date the long-dated Treasury bond has seen its yields tumble by about 25 basis points to the current 4.05%. 
<h3 class="wp-block-heading">Mortgage Applications Dip As Homebuyers Take A Breather</h3>
However, this rate drop did not translate into an increase in mortgage application activity. 
After two consecutive weeks of robust growth, mortgage applications fell sharply, signaling that many potential homebuyers are still in a holding pattern, likely waiting for more clarity on the Federal Reserve&#8217;s future policy direction, which could be hinted at during the upcoming Jackson Hole Symposium.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40466528/jackson-hole-preview-5-important-questions-ahead-of-jerome-powells-fed-speech">Jackson Hole Preview: 5 Important Questions Ahead Of Jerome Powell&#8217;s Fed Speech</a>
Despite the reduced 30-year fixed mortgage rate, overall mortgage applications saw a 10.1% decline compared to the previous week, partially erasing the robust 25% gain recorded over the prior two weeks.
Refinance applications, which tend to be more sensitive to fluctuations in interest rates, dropped by 15%, cutting into the 35% surge observed in the previous week.
Similarly, applications for home purchase mortgages fell by 5%, building on the 8% decline from the prior week. 
<h3 class="wp-block-heading">Thursday&#8217;s Real Estate Stock Movers </h3>
The broader real estate sector, as tracked by the Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>), was up 0.3% during Thursday premarket trading, on track to notch the highest level since September 2022. 
The Top-performing stock within the XLRE ETF was CBRE Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>), up 1.1%.
Taking a closer look at mortgage-linked industries, the iShares Residential and Multisector Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZ#NYSE">REZ</a>) was flat, after closing Tuesday at the highest level since mid-September 2022.
Major premarket gainers within the REZ ETF included Healthcare Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>), up 1.3%, Sabra Health Care REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NYSE">SBRA</a>), up 1.1%, and Universal Health Realty Income Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHT#NYSE">UHT</a>), up 13%
Other mortgage sensitive stocks, such as Redfin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) and Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>), were 1.2% and 0.2% higher, respectively. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40481111/nasdaq-s-p-500-futures-edge-up-as-traders-look-ahead-to-fomc-minutes-strategist-flags-3-trends-that">Nasdaq, S&amp;P 500 Futures Edge Up As Traders Look Ahead To FOMC Minutes: Strategist Flags 3 Trends That Could Help Stocks Withstand Volatility</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Mid Cap

REIT

Sector ETFs

Small Cap

Econ #s

Economics

Federal Reserve

ETFs

Real Estate

CBRE

RDFN

iShares FTSE NAREIT Residential PLUS Capped Index Fund

XLRE

30-Year Mortgage Rates Hit 15-Month Low, But Applications Pull Back After Recent Spikes: Real Estate Stocks React Wednesday (CORRECTED)

Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) &mdash; also known as MPT &mdash; recently concluded the disposition of 11 freestanding emergency department (FSED), primary care, imaging and urgent care facilities in Colorado to University of Colorado Health (&quot;UCHealth&quot;) for $86 million. The move is in line with the company&#39;s capital-recycling strategy.
Reflecting positive sentiments, shares of MPW gained 5.34% on Aug 15 regular trading session on the NYSE.
The company plans to allocate the proceeds obtained from the transaction toward debt reduction and for general corporate purposes.
MPT follows a disciplined capital-recycling strategy, through which it disposes of non-core assets and redeploys the proceeds in premium asset acquisitions and accretive development projects.
In July 2024, MPT sold seven FSED facilities as well as one general acute hospital in Arizona to Dignity Health for approximately $160 million.
In April 2024, the company sold its 75% interest in five Utah hospitals to a new joint venture with an institutional investor for $886 million. This sale generated approximately $1.1 billion of total cash proceeds to MPT. During the same month, it closed on the sale of five facilities in California and New Jersey to Prime Healthcare for a total consideration of $350 million.
This healthcare real estate investment trust (REIT), engaged in the acquisition and development of healthcare facilities, has been making efforts to improve portfolio diversification with respect to the operator.
The company is focusing on the reduction of its exposure to troubled operators and enhancing its scope for stable cashflow generation. Moreover, the company&#39;s successful execution of more than $2.5 billion in liquidity transactions since the beginning of the year through Aug 8, 2024, strengthens its balance sheet position and places it well to fund its short-term liquidity requirements.
Last week, this Birmingham, AL-based REIT reported better-than-expected second-quarter 2024 results. The company reported Normalized Funds from Operations of 23 cents per share, surpassing the Zacks Consensus Estimate of 20 cents.
Over the past six months, shares of this Zacks Rank #1 (Strong Buy) company have gained 38.5% compared with the industry&#39;s growth of 9%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4a/74521.jpg?v=528813046" />
Image Source: Zacks Investment Research
<h3>Other Stocks to Consider</h3>
Some other top-ranked stocks from the healthcare REIT sector are CareTrust REIT (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctre#NYSE">CTRE</a>) and Sabra Healthcare REIT (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbra#NASDAQ">SBRA</a>).
The Zacks Consensus Estimate for CareTrust&#39;s 2024 FFO per share stands at $1.47, indicating an increase of 4.3% from the year-ago reported figure. CTRE sports a Zacks Rank #1 at present.
Sabra currently carries a Zacks Rank #2 (Buy).The Zacks Consensus Estimate for SBRA&#39;s 2024 FFO per share is pinned at $1.41, suggesting year-over-year growth of 6%.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
<a href="https://www.zacks.com/stock/news/2323336/medical-properties-mpw-disposes-of-11-facilities-to-uchealth?cid=CS-BENZ-FT-analyst_blog|company_news_finance_sector-2323336">To read this article on Zacks.com click here.</a>

Penny Stocks

CTRE

Medical Properties Disposes of 11 Facilities to UCHealth

Sabra Sees FY24 AFFO $1.39-$1.42 Vs $1.37 Estimate

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 6.06 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $176.141 million which beat the analyst consensus estimate of $166.032 million by 6.09 percent. This is a 9.29 percent increase over sales of $161.166 million the same period last year.

Sabra Health Care REIT Q2 2024 FFO $0.35 Beats $0.34 Estimate, Sales $176.141M Beat $166.032M Estimate

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Buy and raises the price target from $15 to $16.

Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $16

A significant insider buy by Catherine Cusack, Director at Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>), was executed on May 23, and reported in the recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001492298/000186212824000026//Archives/edgar/data/1492298/000186212824000026/0001862128-24-000026-index.htm">U.S. Securities and Exchange Commission</a> on Thursday unveiled that Cusack made a notable purchase of 7,000 shares of Sabra Health Care REIT, valuing at $101,010.
The latest update on Friday morning shows Sabra Health Care REIT shares up by 1.73%, trading at $14.39.
<h3>Unveiling the Story Behind Sabra Health Care REIT</h3>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Unraveling the Financial Story of Sabra Health Care REIT</h3>
Positive Revenue Trend: Examining Sabra Health Care REIT's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.36% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 67.62%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Sabra Health Care REIT's EPS reflects a decline, falling below the industry average with a current EPS of 0.11.
</li>
</ul>
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.9.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Sabra Health Care REIT's current Price to Earnings (P/E) ratio of 67.38 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.06 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 16.93, Sabra Health Care REIT demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001492298">Check Out The Full List Of Sabra Health Care REIT's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Eye On Growth: Catherine Cusack Adds $101K Of Sabra Health Care REIT Stock To Portfolio

Sabra Health Care REIT: A Promising Value Play In Healthcare Real Estate

Mizuho analyst Vikram Malhotra downgraded Sabra Health Care (SBRA) to Neutral from Outperform with an unchanged price target of $20. The firm says ...

Sabra Health Care downgraded to Neutral from Outperform at Mizuho

NAV Monitor: U.S. Equity REITs End November At 6.5% Median Discount

Sabra Health Care REIT downgraded at Mizuho on increased regulatory risk, full valuations

CareTrust REIT: An Acquisition Titan That's Still A Buy For Long-Term Investors

In a report released today, Michael Lewis from Truist Financial maintained a Buy rating on Sabra Healthcare REIT (SBRA – Research Report), with a p...

Truist Financial Remains a Buy on Sabra Healthcare REIT (SBRA)

2025 Analyst Outlook: Brad Thomas On REIT Sector Opportunities And Market Conditions

Sabra Health Care REIT: A High-Yielding Gift Just In Time For The New Year

Jefferies lowered the firm's price target on Sabra Health Care to $20 from $21 and keeps a Buy rating on the shares as part of a 2025 outlook. With...

Sabra Health Care price target lowered to $20 from $21 at Jefferies

Sabra Health Care REIT: Buy Into Future Demand For Skilled Nursing Facilities

BBRE

CHCT

CURB

EPRT

FREL

GMRE

GOOD

GOODN

GOODO

ILPT

IRET

KBWY

LADR

PFFR

PGRE

PLDGP

PPTY

REGCO

REGCP

SCHH

SEVN

SITC

SRVR

STRW

TMUS

USRT

VICI

VRAI

WELL

Press Releases

Sabra Health Care REIT, Inc. Announces Second Quarter 2024 Earnings Release Date and Conference Call

Sabra Publishes Fourth Annual Sustainability Report

Sabra Reports Second Quarter 2024 Results; Increases 2024 Guidance

Sabra Health Care REIT, Inc. to Participate in the BofA Securities 2024 Global Real Estate Conference

Sabra Health Care REIT, Inc. to Attend Fall Conferences

Sabra Health Care REIT, Inc. Announces Third Quarter 2024 Earnings Release Date and Conference Call

Moody's Upgrades Sabra Health Care REIT, Inc.'s Outlook to Positive, Affirms Credit Rating

Sabra Reports Third Quarter 2024 Results; Updates 2024 Guidance

Sabra Health Care REIT, Inc. to Attend Nareit's REITworld 2024 Annual Conference

Comments

Sabra Health Care REIT

空売り

Sabra Health Care REIT (NASDAQ:SBRA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル